Go Pro
→ A $382 trillion migration and the position no one is talking about (From Awesomely) (Ad)tc pixel Free BIAFW Stock Alerts

bioAffinity Technologies (BIAFW) Competitors

bioAffinity Technologies logo
$0.13 +0.06 (+77.10%)
As of 08/25/2026 03:39 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

BIAFW vs. ALVOW, APLMW, ARAV, BIVIW, and CDIOW

Should you buy bioAffinity Technologies stock or one of its competitors? bioAffinity Technologies's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), BioVie (BIVIW), and Cardio Diagnostics (CDIOW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does bioAffinity Technologies compare to Alvotech?

bioAffinity Technologies (NASDAQ:BIAFW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

In the previous week, Alvotech had 2 more articles in the media than bioAffinity Technologies. MarketBeat recorded 5 mentions for Alvotech and 3 mentions for bioAffinity Technologies. Alvotech's average media sentiment score of 0.36 beat bioAffinity Technologies' score of 0.30 indicating that Alvotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
bioAffinity Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alvotech
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
Alvotech$491.95MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
Alvotech N/A N/A N/A

Summary

Alvotech beats bioAffinity Technologies on 3 of the 3 factors compared between the two stocks.

How does bioAffinity Technologies compare to Apollomics?

Apollomics (NASDAQ:APLMW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, bioAffinity Technologies had 2 more articles in the media than Apollomics. MarketBeat recorded 3 mentions for bioAffinity Technologies and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.87 beat bioAffinity Technologies' score of 0.30 indicating that Apollomics is being referred to more favorably in the media.

Company Overall Sentiment
Apollomics Very Positive
bioAffinity Technologies Neutral

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

Summary

Apollomics beats bioAffinity Technologies on 2 of the 3 factors compared between the two stocks.

How does bioAffinity Technologies compare to Aravive?

Aravive (NASDAQ:ARAV) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AraviveN/AN/AN/A-$0.90N/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

In the previous week, bioAffinity Technologies had 3 more articles in the media than Aravive. MarketBeat recorded 3 mentions for bioAffinity Technologies and 0 mentions for Aravive. bioAffinity Technologies' average media sentiment score of 0.30 beat Aravive's score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
bioAffinity Technologies Neutral

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

bioAffinity Technologies beats Aravive on 3 of the 5 factors compared between the two stocks.

How does bioAffinity Technologies compare to BioVie?

bioAffinity Technologies (NASDAQ:BIAFW) and BioVie (NASDAQ:BIVIW) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, bioAffinity Technologies had 1 more articles in the media than BioVie. MarketBeat recorded 3 mentions for bioAffinity Technologies and 2 mentions for BioVie. bioAffinity Technologies' average media sentiment score of 0.30 beat BioVie's score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company Overall Sentiment
bioAffinity Technologies Neutral
BioVie Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
BioVie N/A N/A N/A

Summary

bioAffinity Technologies beats BioVie on 3 of the 3 factors compared between the two stocks.

How does bioAffinity Technologies compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIOW) and bioAffinity Technologies (NASDAQ:BIAFW) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardio Diagnostics$14.45KN/AN/AN/AN/A
bioAffinity Technologies$5.85MN/AN/AN/AN/A

In the previous week, bioAffinity Technologies had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for bioAffinity Technologies and 2 mentions for Cardio Diagnostics. Cardio Diagnostics' average media sentiment score of 0.44 beat bioAffinity Technologies' score of 0.30 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company Overall Sentiment
Cardio Diagnostics Neutral
bioAffinity Technologies Neutral

Company Net Margins Return on Equity Return on Assets
Cardio DiagnosticsN/A N/A N/A
bioAffinity Technologies N/A N/A N/A

Summary

bioAffinity Technologies beats Cardio Diagnostics on 2 of the 3 factors compared between the two stocks.

Get bioAffinity Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIAFW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIAFW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIAFW vs. The Competition

Export
MetricbioAffinity TechnologiesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$4.02B$7.29B$12.75B
Dividend YieldN/A3.63%2.53%10.79%
P/E RatioN/A11.80272.0224.14
Price / SalesN/A1,351.89621.1297.55
Price / CashN/A103.6478.5753.12
Price / BookN/A16.9013.146.22
Net IncomeN/A-$22.76M$3.47B$348.07M
7 Day Performance6.83%1.10%0.91%0.50%
1 Month PerformanceN/A11.35%8.29%4.68%
1 Year PerformanceN/A56.41%25.57%16.61%

bioAffinity Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIAFW
bioAffinity Technologies
N/A$0.13
+77.1%		N/A+90.0%$0.00$5.85MN/A10
ALVOW
Alvotech
N/A$0.22
+14.4%		N/A-58.0%$0.00$559.42MN/A4
APLMW
Apollomics
N/A$0.02
-5.0%		N/A-32.6%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIVIW
BioVie
N/A$0.24
-17.2%		N/AN/A$0.00N/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BIAFW) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Trump Unleashes "Banned" American Fuel
A newly reopened American mine holds a fuel source so potent that one pound can generate as much energy as 16,...
Monument Traders Alliance | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel